

Ezrin(Phospho-Tyr353) Antibody

Catalog No: #11063



Package Size: #11063-1 50ul #11063-2 100ul

Orders: order@signalwayantibody.com

Support: tech@signalwayantibody.com

Description

Product Name	Ezrin(Phospho-Tyr353) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	WB IHC
Species Reactivity	Hu
Specificity	The antibody detects endogenous level of Ezrin only when phosphorylated at tyrosine 353.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of tyrosine 353 (Q-D-Y(p)-E-E) derived from Human EZRIN.
Target Name	Ezrin
Modification	Phospho
Other Names	Cytovillin; EZRI; VIL2; Villin 2; p81
Accession No.	Swiss-Prot: P15311NCBI Protein: NP_001104547.1
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.


Application Details

Predicted MW: 81kd


Western blotting: 1:500~1:1000

Immunohistochemistry: 1:50~1:100

Images



Western blot analysis of extracts from 293 cells untreated or treated with EGF using Ezrin(Phospho-Tyr353) Antibody #11063.



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Ezrin(Phospho-Tyr353) Antibody #11063(left) or the same antibody preincubated with blocking peptide(right).

Background

Probably involved in connections of major cytoskeletal structures to the plasma membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with PLEKHG6, required for normal macropinocytosis.

Zhao H, et al. (2004) *Proc Natl Acad Sci U S A* 101 (25): 9485-9490.

Wang Q, et al. (2003) *J Biol Chem* 278(48): 47731-47743.

Gautreau A, et al. (1999) *Proc Natl Acad Sci U S A* 96(13): 7300-7305.

Crepaldi T, et al. (1997) *J Cell Biol* 138(2): 423-34.

Published Papers

el at., Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer. In *BMC Cancer* on 2014 Mar 15 by Tiefeng Jin, Jingchun Jin et al ..PMID: 24629131, , (2014)

[PMID:24629131](#)

el at., Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas. In *Hum Pathol* on 2013 Aug by Yasunori Oda, Shinichi Aishima, et al..PMID: 23465281, , (2013)

[PMID:23465281](#)

Yasunori Oda MD, Shinichi Aishima PhD, Katsuya Morimatsu PhD el at., Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas., *Human Pathology*, 44(8):1487-1498 (2012)

[PMID:23465281](#)

Yazhou Cui, Tianliang Li, Denglu Zhang el at., Expression of Ezrin and Phosphorylated Ezrin (pEzrin) in Pancreatic Ductal Adenocarcinoma., *Cancer Investigation*, 28(3) 242-247(2010)

[PMID:20158339](#)

el at., Expression of Ezrin and Phosphorylated Ezrin (pEzrin) in Pancreatic Ductal Adenocarcinoma. In *Cancer Invest* on 2010 Mar by Cui Y1, Li T, et al..PMID:20158339, , (2010)

[PMID:20158339](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.